Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics, a clinical stage biotechnology company, has appointed Elaine Waller as its new senior vice president of regulatory affairs and Christopher Pawlowicz as senior vice president of human resources, as well as the promotion of Jonathan Drachman to vice president of early clinical development.
Subscribe to our email newsletter
Prior to joining Seattle Genetics, Dr Waller was with Sonus Pharmaceuticals, where she served as senior vice president of regulatory affairs/quality assurance and clinical research until its merger with OncoGenex Pharmaceuticals.
Prior to Seattle Genetics, Mr Pawlowicz was senior vice president of human resources and administration at MedPointe Pharmaceuticals, a specialty pharmaceutical company.
Dr Drachman has been with Seattle Genetics since 2004, serving most recently as senior medical director.
Clay Siegall, president and CEO of Seattle Genetics, said: “Jonathan’s promotion reflects his dedication and the substantial drug development acumen he has demonstrated in his four years with the company. Our team is further strengthened by the additions of Elaine and Chris who have extensive experience in their respective fields.”